These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 21913886)
1. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications. Bodera P; Stankiewicz W Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886 [TBL] [Abstract][Full Text] [Related]
2. Properties of thalidomide and its analogues: implications for anticancer therapy. Teo SK AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of thalidomide and its analogues. De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255 [TBL] [Abstract][Full Text] [Related]
4. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291 [TBL] [Abstract][Full Text] [Related]
5. Thalidomide analogues as anticancer drugs. Aragon-Ching JB; Li H; Gardner ER; Figg WD Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):167-74. PubMed ID: 17975653 [TBL] [Abstract][Full Text] [Related]
7. The potential of immunomodulatory drugs in the treatment of solid tumors. Dalgleish A; Galustian C Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide - current understanding of mechanistic properties. Tageja N Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296 [TBL] [Abstract][Full Text] [Related]
9. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Lacy MQ; Tefferi A Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284 [TBL] [Abstract][Full Text] [Related]
10. The thalidomide saga. Melchert M; List A Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076 [TBL] [Abstract][Full Text] [Related]
11. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856 [TBL] [Abstract][Full Text] [Related]
15. Thalidomide and lenalidomide in the treatment of multiple myeloma. Kumar S; Rajkumar SV Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621 [TBL] [Abstract][Full Text] [Related]
16. IMiDs: a novel class of immunomodulators. Knight R Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014 [TBL] [Abstract][Full Text] [Related]
17. Lenalidomide mode of action: linking bench and clinical findings. Davies F; Baz R Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Lopez-Millan B; Diaz de la Guardia R; Roca-Ho H; García-Herrero CM; Lavoie JR; Rosu-Myles M; Gonzalez-Rey E; O'Valle F; Criado G; Delgado M; Menendez P Exp Mol Med; 2017 Feb; 49(2):e290. PubMed ID: 28154372 [TBL] [Abstract][Full Text] [Related]
19. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Bartlett JB; Dredge K; Dalgleish AG Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291 [No Abstract] [Full Text] [Related]
20. Mechanism of action of lenalidomide in hematological malignancies. Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]